According to a new report, published by KBV research, The Global Onychomycosis Market size is expected to reach $4.5 billion by 2028, rising at a market growth of 4.8% CAGR during the forecast period.
The White Superficial segment is showcasing a CAGR of 5% during (2022 - 2028). This is because this particular nail fungal infection is less common. Only toenails are impacted, and the fungus colonizes the surface of the nail plate, leaving behind numerous white, friable nail plate patches. This infection always requires a comprehensive approach to treatment. This infection is brought on by T. mentagrophytes. It is much rarer than other forms of onychomycosis.
The Topical segment acquired maximum revenue share in the Global Onychomycosis Market by Treatment in 2021 thereby, achieving a market value of $2.7 billion by 2028. The growth of the segment is owed to the lower occurrence of the negative effects of topical therapies. Additionally, new topical formulations that respond more quickly than currently existing topical medicines are being studied. For instance, JUBLIA, a topical formulation of efinaconazole developed for treating onychomycosis, was approved by the American Podiatric Medical Association (APMA) in December 2021.
The North America market dominated the Global Onychomycosis Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1.8 billion by 2028. The Europe market is exhibiting a CAGR of 4.6% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 5.6% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/onychomycosis-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.
By Type
By Treatment
By Geography
Companies Profiled
Unique Offerings 
